Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

MacroGenics Shares Jump 10% in 2 Days Since Other

MacroGenics Reports 27% Response Rate for MGC026 in Phase 1 Cancer Trial

+10.22% in 2 days $2.25 when we broke this story → $2.48 at 10:40 AM ET, 27 Oct 2026

MacroGenics announced positive interim Phase 1 data for its B7-H3-directed antibody-drug conjugate, MGC026, across multiple solid tumor types. The study highlighted significant antitumor activity in heavily pretreated head and neck cancer patients, supporting an upcoming combination study with pembrolizumab.

Lab, experiment, test, chemistry. Stock photo illustrating MacroGenics' other story.
MACROGENICS INC · Healthcare · Photo: fernandozhiminaicela / Pixabay

Key highlights

  • Interim Phase 1 data showed a 27% best overall response rate in 22 evaluable SCCHN patients
  • Confirmed objective response rate reached 29% for patients in the dose-escalation phase receiving at least 6 mg/kg
  • Median duration of response was 10.2 months among responders in the dose-escalation portion
  • Safety profile remains manageable with no reported cases of interstitial lung disease or ocular toxicity
  • Management selected 7.5 mg/kg every three weeks as the recommended dose for further expansion studies

Phase 1 Clinical Outcomes

MacroGenics presented interim Phase 1 results for MGC026, its B7-H3-directed antibody-drug conjugate (ADC), at the 2026 European Society for Medical Oncology (ESMO) Congress. The trial evaluated the therapeutic candidate in patients with advanced solid tumors who had received a median of four prior lines of therapy. In the dose-escalation phase, 17 evaluable patients across 10 different tumor types demonstrated a confirmed objective response rate of 29% and a disease control rate of 65%. Pharmacokinetic data supported the selection of a 7.5 mg/kg dose for ongoing tumor-specific expansion, particularly in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Strategic Development Plans

  • Initiation of a front-line metastatic SCCHN cohort evaluating MGC026 in combination with pembrolizumab
  • Expansion of the current SCCHN monotherapy cohort to reach a target enrollment of 40 patients
  • Continued monitoring of safety following reports of zero treatment-related discontinuations in the SCCHN cohort
  • Evaluation of MGC026 potential as a differentiated B7-H3 targeting agent using proprietary drug-linker technology

Business and Pipeline Status

Headquartered in Rockville, Maryland, MacroGenics is refining its clinical focus following the recent $122.5 million sale of its GMP manufacturing operations to Bora Pharmaceuticals in July 2026. This divestiture, combined with regulatory milestones such as the $24.5 million payment following the U.S. approval of TZIELD, has bolstered the company's balance sheet. Management currently projects that its pro forma cash and marketable securities will fund operations through 2028. The pipeline remains active with other candidates, including the recent dosing of the first patient in a Phase 1 study of MGC030 for advanced solid tumors.

Financial and Market Context

MacroGenics currently maintains a market capitalization of approximately $143.3 million. Despite the clinical update presented at ESMO, the stock experienced a significant price decline of 38.02%, pushing the 14-day relative strength index (RSI) to 25.3, which technical analysts generally associate with oversold conditions. The company reported annual revenue of $149.5 million for the most recent fiscal year. Investors are looking forward to the release of third-quarter 2026 financial results, estimated for early November, and the presentation of Lorigerlimab Phase 2 data scheduled for later in the current ESMO Congress.

MACROGENICS INC share price · last month
Line chart of MACROGENICS INC's share price over the last month, from $3.33 on 19 Oct → $2.17 on 16 Nov; our story on 23 Oct at $2.25.

Down 3.6% since our story on 23 Oct: $2.25 when we broke it → $2.17 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$3.33
20 Oct$3.49
21 Oct$3.59
22 Oct$3.63
23 Oct$2.25
26 Oct$2.19
27 Oct$2.44
28 Oct$2.47
29 Oct$2.38
30 Oct$2.40
2 Nov$2.33
3 Nov$2.33
4 Nov$2.31
5 Nov$2.22
6 Nov$2.33
9 Nov$2.34
10 Nov$2.42
11 Nov$2.32
12 Nov$2.29
13 Nov$2.20
16 Nov$2.17
Earlier announcements by MACROGENICS INC
DateAnnouncementAmount
15 Oct 2026MacroGenics announced first patient dosed in Phase 1 study of MGC030 in advanced solid tumorsSource: ir.macrogenics.com–
11 Aug 2026MacroGenics announced achievement of milestone following Gilead's option exercise to license preclinical bispecific programSource: ir.macrogenics.com$10.0 Million
02 Jul 2026MacroGenics completed sale of GMP manufacturing operations to Bora PharmaceuticalsSource: ir.macrogenics.com$122.5 Million
22 Jun 2026MacroGenics announced regulatory milestone payment from Sanofi following U.S. approval of TZIELDSource: ir.macrogenics.com$24.5 Million
11 May 2026MacroGenics entered into agreement to sell GMP manufacturing operations to Bora PharmaceuticalsSource: ir.macrogenics.com$122.5 Million

Management commentary

“The emerging profile of MGC026 reinforces our conviction that this molecule has the potential to play an important and differentiated role in the treatment of advanced solid tumors.”

Eric Risser, President and Chief Executive Officer
MACROGENICS INC · financial snapshot
Share price$2.25
Market cap$143M
Revenue (annual)$150M
1-month price change-40.79%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by MacroGenics, Inc. announcing interim Phase 1 clinical trial results for MGC026 presented at the ESMO 2026 Congress.

Read the filing ↗

Track MACROGENICS INC live

Get the next MACROGENICS INC SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.